Edwards Lifesciences CORP (EW) — Who Owns This Stock? 13F Breakdown (Q2 2026)

EW ranks #296 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1335 institutions disclose a position in EW, but none treat it as a major bet — even Wellcome Trust LTD, its most concentrated holder, allocates just 4.8% of its own portfolio to it.

DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main has added to its EW position for two straight quarters, increasing it by $517.1M to reach $1.2B today.

Jennison Associates LLC has trimmed its EW position for two straight quarters, cutting it by $1.2B while still holding $21.6M.

EW is up 0.1% today, and institutions have been net buyers of $13.9B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

EW posted net income of $1.0B over the trailing twelve months, and currently trades at a P/E of 52.9.

• Profitable — net income of $1.0B over the trailing twelve months
• Revenue grew 14.6% year over year
• Net income declined year over year, from $4.1B to $1.0B
• Generated $1.6B in positive operating cash flow
• Current ratio of 3.72x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.33x equity — within a conventional range